A vaccine that is able to work as a treatment for HIV-infected patients has been an elusive goal. Now experiments on macaques suggest that injections of modified dendritic cells might boost immunity to hold back disease progression (pages 27–32).
This is a preview of subscription content, log in via an institution to check access.
Courtesy of Marie Larsson
References
Rosenberg, E.S. et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407, 523–526 (2000).
Altfeld, M. et al. HIV-1 superinfection despite broad CD8+ T cell responses containing replication of the primary virus. Nature 420, 434–439 (2002).
Oxenius, A. et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc. Natl. Acad. Sci. USA 99, 13747–13752 (2002).
Lu, W., Wu, X., Lu, Y., Weizhong, G. & Andrieu, J. Therapeutic dendritic-cell vaccine for simian AIDS. Nature Med. 9, 27–32 (2003).
Schmitz, J.E. et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283, 857–860 (1999).
Jin, X. et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991–998 (1999).
Rosenberg, E.S. et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278, 1447–1450 (1997).
Parren, P.W., Moore, J.P., Burton, D.R. & Sattentau, Q.J. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity. Aids 13 (Suppl. A), S137–162 (1999).
Banchereau, J. et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767–811 (2000).
Rossio, J.L. et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72, 7992–8001 (1998).
Bender, A., Bui, L.K., Feldman, M.A., Larsson, M. & Bhardwaj, N. Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. J. Exp. Med. 182, 1663–1671 (1995).
Bhardwaj, N., Young, J.W., Nisanian, A.J., Baggers, J. & Steinman, R.M. Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses. J. Exp. Med. 178, 633–642 (1993).
Dhodapkar, M.V. et al. Rapid generation of broad T-cell immunity in humans after a single injection of maturation dendritic cells. J. Clin. Invest. 104, 173–180 (1999).
Ludewig, B. et al. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. J. Immunol. 163, 1839–1844 (1999).
Altfeld, M. et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J. Exp. Med. 193, 169–180 (2001).
Barouch, D.H. et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335–339 (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bhardwaj, N., Walker, B. Immunotherapy for AIDS virus infections: Cautious optimism for cell-based vaccine. Nat Med 9, 13–14 (2003). https://doi.org/10.1038/nm0103-13
Issue Date:
DOI: https://doi.org/10.1038/nm0103-13
- Springer Nature America, Inc.
This article is cited by
-
Epidemic modeling with discrete-space scheduled walkers: extensions and research opportunities
BMC Public Health (2009)
-
Therapeutic vaccines against HIV need international partnerships
Nature Reviews Immunology (2003)